ProGen. Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ProGen. Co., Ltd. - overview
Established
1998
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Based in Seoul, South Korea, and founded in 1998, ProGen. Co. , Ltd. operates as a research and development focused biotechnology company that aims to deliver new drugs based on its own platform that they had developed which is called NTIG to develop treatment for cancer and immune diseases.
Current Investors
Yuhan Corporation, SL BIGEN
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.progen.co.kr/
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
ProGen. Co., Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | ProGen. Co., Ltd. | - | ||||||||
| Buyout | Completed | ProGen. Co., Ltd. | - | ||||||||
| Unspecified Exit | Completed | Genexine, Inc. | - | ||||||||
| Unspecified Exit | Completed | Genexine, Inc. | - | ||||||||
| PIPE | Completed | Genexine, Inc. | - |
Displaying 1 - 5 of 6
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.